DB04880 - Enoximone
| Identification | |
|---|---|
| Name | Enoximone |
| Accession Number | DB04880 |
| Type | small molecule |
| Description | Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries. |
| Structure |
|
| Categories (*) | |
| Molecular Weight | 248.301 |
| Groups | approved |
| Monoisotopic Weight | 248.061948328 |
| Pharmacology | |
| Indication | For the treatment of congestive heart failure. |
| Mechanism of action | Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation. |
| Absorption | Bioavailabvility is 50% following oral administration. |
| Protein binding | 85% |
| Biotransformation | Hepatic oxidation |
| Route of elimination | Not Available |
| Toxicity | Not Available |
| Affected organisms |
|
| Interactions | |
| Drug Interactions | Not Available |
| Food Interactions | Not Available |
Targets
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | |
|---|---|
| Name | cGMP-inhibited 3',5'-cyclic phosphodiesterase A |
| Gene Name | PDE3A |
| Pharmacological action | yes |
| Actions | inhibitor |
| References |
|
| DTHybrid score | Not Available |